Skip to main content
OpenTrials

Clinical trial condition

Urothelial Carcinoma

Explore clinical trials studying Urothelial Carcinoma. Study availability and eligibility vary by location and protocol.

239 public trials 74 recruiting studies
Refine in advanced search Browse all conditions

Urothelial Carcinoma trial results

Completed

Patient-reported Outcomes in Bladder Cancer

NCT03584659

Conditions
Bladder Cancer, Carcinoma, Carcinoma, Transitional Cell, +14 more
Locations
  • Aalborg University Hospital Aalborg, Denmark
  • Department of Oncology, Rigshospitalet Copenhagen, Denmark
  • Department of Oncology Herlev, Denmark
  • Odense University Hospital Odense, Denmark
View Trial Details
Completed

Testing the PD-1 Inhibitor Pembrolizumab as Maintenance Therapy After Initial Chemotherapy in Metastatic Bladder Cancer

NCT02500121

Conditions
Bladder Cancer, Carcinoma, Carcinoma, Transitional Cell, +14 more
Locations
  • University of Arizona at Dignity Health St. Joseph's Phoenix, Arizona, United States
  • City of Hope Comprehensive Cancer Center Duarte, California, United States
  • University of Southern California Los Angeles, California, United States
  • Georgetown University Washington D.C., District of Columbia, United States
View all 28 locations
View Trial Details
Completed

A Phase 2b Study of UGN-102 for Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer

NCT03558503

Conditions
Bladder Cancer, Carcinoma, Carcinoma, Transitional Cell, +16 more
Locations
  • Mayo Clinic Cancer Center Phoenix, Arizona, United States
  • Arkansas Urology Little Rock, Arkansas, United States
  • Loma Linda University Loma Linda, California, United States
  • Providence Medical Institute Santa Monica, California, United States
View all 19 locations
View Trial Details
Completed

A Study of Atezolizumab (Tecentriq®) in Ministry of Food and Drug Safety (MFDS)-Approved Indication(s)

NCT03232593

Conditions
Adenocarcinoma, Breast Diseases, Breast Neoplasms, +27 more
Locations
  • Dongnam Inst.of Radiological & Medical Sciences Busan, South Korea
  • Inje University Busan Paik Hospital Busan, South Korea
  • Inje university Haeundae Paik Hospital Busan, South Korea
  • Dong-A University Hospital Busan, South Korea
View all 56 locations
View Trial Details
Completed

Phase 2 Study of Docetaxel +/- OGX-427 in Patients With Relapsed or Refractory Metastatic Bladder Cancer

NCT01780545

Conditions
Bladder Cancer, Carcinoma, Carcinoma, Transitional Cell, +14 more
Locations
  • University of Alabama Hematology Oncology Clinic at Medical West Birmingham, Alabama, United States
  • City of Hope: Duarte Duarte, California, United States
  • City of Hope: Antelope Valley Lancaster, California, United States
  • USC: Norris Comprehensive Cancer Center Los Angeles, California, United States
View all 35 locations
View Trial Details
Completed

First-Line Gemcitabine, Cisplatin + Ipilimumab for Metastatic Urothelial Carcinoma

NCT01524991

Conditions
Carcinoma, Carcinoma, Transitional Cell, Neoplasms, +3 more
Locations
  • City of Hope: Duarte Duarte, California, United States
  • IU Health Goshen Hospital Goshen, Indiana, United States
  • Indiana University Melvin & Bren Simon Cancer Center Indianapolis, Indiana, United States
  • IU Health Central Indiana Cancer Centers Indianapolis, Indiana, United States
View Trial Details

Related conditions